This Biotech Had Positive Data In Gene Therapy — But It Wasn't Enough

BioMarin Pharmaceutical stock dipped Tuesday after its gene therapy results underwhelmed investors and raised "more questions" regarding hemophilia A treatment.  


CLICK HERE TO READ THE FULL STORY

Subscribe and Get Breaking News Sent to Your Inbox!

  • White Instagram Icon
  • White Facebook Icon

© 2019- 2020 HEMO TIMES IS A SUBSIDIARY OF RARE HEALTH NETWORK, LLC